Overview

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Status:
Completed
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Kadmon Corporation, LLC
Collaborator:
Quotient Sciences
Treatments:
Hydroxyitraconazole
Itraconazole
Omeprazole
Rabeprazole
Rifampin